Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases

Authors:   V.A. Trivillin,M.A. Garabalino,L.L. Colombo,S.J. González,R.O. Farías,A. Monti Hughes,E.C.C. Pozzi,S. Bortolussi,S. Altieri,M.E. Itoiz,R.F. Aromando,D.W. Nigg,A.E. Schwint,
Journal: Applied Radiation and Isotopes
https://doi.org/10.1016/j.apradiso.2013.11.115
Abstract: BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25–76ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.